BENITEC BIOPHARMA LIMITED The instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
45,586,681 | 4,363,185 | 246,760 | 1,366,350 |
The motion was carried as an ordinary resolution on a show of hands.
Re-‐election of Director - Dr John ChiplinThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
41,834,713 | 9,180,043 | 103,409 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
Election of Director - Ms. Megan BostonThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
47,929,608 | 3,044,475 | 144,082 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
Approval of 10% Placement CapacityThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
46,916,649 | 3,889,171 | 107,345 | 1,771,350 |
The motion was carried as a special resolution on a show of hands.
Ratification of Prior Issue of Shares to Nant Capital, LLCThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
19,969,429 | 1,799,241 | 43,676 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
Approval of New Issue of Shares to Nant Capital, LLCThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
18,152,197 | 3,621,473 | 38,676 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
Election of Director - Dr. Jerel BanksThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
49,502,632 | 1,508,451 | 107,082 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
Approval of New Issue of Shares to Sophisticated and Institutional InvestorsThe instructions given to validly appointed proxies in respect of the resolution were as follows:
For | Against | Abstain | Proxy's discretion |
46,813,729 | 4,279,146 | 25,290 | 1,566,350 |
The motion was carried as an ordinary resolution on a show of hands.
For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.
Australia Investor Relations United States Investor RelationsMarket Eye Orla Keegan Director
Tel: +61 (2) 8097 1201
Email: orla.keegan@marketeye.com.au
M Group Strategic Communications Jay Morakis
Managing Director Tel: +1 212.266.0190
Email: jmorakis@MGroupSC.com
About Benitec Biopharma Limited:Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-‐silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-‐based therapeutics for chronic and life-‐ threatening human conditions including hepatitis B, wet age-‐related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.
Safe Harbor Statement:This press release contains "forward-‐looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-‐looking statements that may be in the press release are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialize its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-‐licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-‐looking statements as a prediction of actual future results.
Benitec Biopharma Ltd. published this content on 14 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 14 December 2016 01:12:07 UTC.
Original documenthttp://blt.live.irmau.com/irm/PDF/1774_0/AGMPROXYVOTES
Public permalinkhttp://www.publicnow.com/view/EA788EE01F43AF125727E0AFAABCC5B12CA5F070
